The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Acelyrin Inc. (SLRN) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$16.25, or -58.24%, to $11.65. The Acelyrin Inc. has recorded 2,026,751 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $27.90 and fluctuated between $28.24 as its day high and $27.40 as its day low. The current market capitalization of Acelyrin Inc. is $2.69B. A total of 2.43 million shares were traded on the day, compared to an average of 801.35K shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, SLRN has seen 5 BUY and 0 SELL insider trades, representing the acquisition of 1,353,503 and the disposition of 0 shares. Over the last 12 months, there were 26 BUYs and 7 SELLs from insiders. Insiders purchased 24,637,978 shares during that period but sold 3,187,111.
In the most recent transaction, Westlake BioPartners Fund II, bought 1,250,000 shares of SLRN for 18.00 per share on May 09. After the transaction, the 10% Owner now owns 9,790,729 company shares. In a previous transaction on May 09, SEIDENBERG BETH C bought 1,250,000 shares at 18.00 per share. SLRN shares that Director owns now total 9,790,729.
Among the insiders who bought shares, SEIDENBERG BETH C acquired of 60,000 shares on May 09 at a per-share price of $18.00. This resulted in the Director holding 60,000 shares of SLRN after the transaction. In another insider transaction, Gosebruch Henry O bought 50,000 shares at $18.00 per share on May 09. Company shares held by the Director now total 50,000.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for SLRN in the last 3 months, the mean price target is $45.50 with high estimates of $68.00 and low estimates of $31.00. In terms of 52-week highs and lows, SLRN has a high of $29.88 and a low of $16.60.
As of this writing, SLRN has an earnings estimate of -$0.44 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.29 per share and a lower estimate of -$0.65. The company reported an EPS of -$8.61 in the last quarter, which was 20.90% higher than expectations of -$10.89.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. SLRN’s latest balance sheet shows that the firm has $102.24M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was $12.28, while its Total Shareholder’s Equity was -$42.06M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SLRN is Buy with a score of 5.00.